Treatment with atumelnant resulted in rapid, sustained lowering of androstenedione (in all eight patients that completed the fourth cohort). Seven out of these eight patients continued to maintain ...
The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the companies’ respective drug applications. Sanofi revealed Dec. 24 that the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The same drug is under FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback